Results 191 to 200 of about 10,571,700 (283)

Emerging medical therapies in crush syndrome - progress report from basic sciences and potential future avenues. [PDF]

Ren Fail, 2020
Li N, Wang X, Wang P, Fan H, Hou S, Gong Y.   +5 more
europepmc   +1 more source

Reporting Progress

American Journal of Public Health and the Nations Health, 1936
openaire   +3 more sources

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Brief progress report from the intersocietal working group on differentiated thyroid cancer. [PDF]

Eur J Nucl Med Mol Imaging, 2020
Verburg FA, Ahuja S, Avram AM, Bardiès M, Bernet V, Bourguet P, Führer-Sakel D, Draganescu C, Daniels GH, Greenspan B, Gulec S, Hegedüs L, Jonklaas J, Luster M, Oyen W, Smit J, Tuttle RM, Zerdoud S, Van Nostrand D.   +18 more
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

GD 358 in 1994: a progress report

Open Astronomy, 1995
Nather R. E.
doaj   +1 more source

Commentary: Mediation and Moderation: An Historical Progress Report. [PDF]

J Pediatr Psychol, 2019
Holmbeck GN.
europepmc   +1 more source